To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

SAGE-718

From Wikipedia, the free encyclopedia

SAGE-718
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1

SAGE-718 (Nonproprietary Name: Dalzanemdor[1]) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[2] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.[3] SAGE-718 is an analog of the neurosteroid 24S-hydroxycholesterol.[3]

As of 2022, SAGE-718 is in Phase II clinical trials[3] for Alzheimer's disease,[4][5][6] Parkinson's disease, and Huntington's disease.[7][8]

References

  1. ^ "Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor". Sage Therapeutics. December 5, 2023.
  2. ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. 65 (13): 9063–9075. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
  3. ^ a b c "SAGE-718". ALZFORUM.
  4. ^ Shapiro L (5 April 2022). "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
  5. ^ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  6. ^ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena.
  7. ^ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America. 22 February 2022.
  8. ^ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This page was last edited on 9 January 2024, at 13:26
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy